- Pk:1 KIT
- Description:EarlyTox™ Caspase-3/7 R110 Explorer Assay Kit, 1 vial of Rhodamine 110 (80 µM, 1 ml), 2 vials of caspase-3 inhibitor (5 mM, 20 µl), 2 vials of DEVD-R110 (2 mM, 500 µl), 2 vials of lysis buffer (10 ml), sufficient reagents for 2 plates (96- or 384-wells)
- Seq:01
EarlyTox™ Cell Viability Assay Kits are a family of fluorescence-based reagents for the assessment of cell viability, cell proliferation, and various apoptosis events using mammalian cells. Optimised for use with microplate readers, these assay kits employ a no-wash, homogeneous assay protocol that enables characterisation of a full concentration-response profile of test compounds.
- Optimal data quality for microplate reader assay
- Simplified, homogeneous experimental protocol
- Preconfigured SoftMax Pro Software protocols
EarlyTox™ Caspase-3/7 R110 Assay Kit enables analysis of apoptosis based on caspase-3/7 activity and its consensus target sequence, Asp-Glu-Val-Asp (DEVD). Caspase-3 and caspase-7 are proteases that are activated during the execution phase of apoptosis. This kit provides a single-step, homogenous assay that is specifically designed for microplate readers. The fluorogenic substrate (Ac-DEVD)2-R110 contains two DEVD consensus target sequence and is completely hydrolysed in cell lysate by the enzymes. Hydrolysis of both DEVD peptides releases the green fluorescent dye R110, resulting in a substantial fluorescence increase, with excitation at 490 nm and emission at 520 nm. The assay kit includes the competitive caspase-3/7 inhibitor Ac-DEVD-CHO for use as a negative control. R110 is also provided in the kit for generating a standard curve, which can be used for quantifying caspase-3 activity.